Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssaf-Harofeh Medical Center
About this trial
Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome
Eligibility criteria
Qualifiers
Age above 18 years
Reported post COVID-19 cognitive deterioration that effect quality of life and persist at least 3 months after confirmed infection.
Subject willing and able to read, understand and sign an informed consent
Disqualifiers
Inability to attend scheduled clinic visits and/or comply with the study protocol
History of traumatic brain injury (TBI) or any other non COVID brain pathology
Active malignancy
Substance use at baseline
Trial design
Treatments tested in this trial
- Hyperbaric oxygen
- Sham
Treatment groups
91 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov